Allogene Showcases BCMA/CD70 Dual AlloCAR T Data and Dagger® Autoimmune Platform at AACR 2026
On April 20, Allogene will present preclinical data on its BCMA/CD70 dual AlloCAR T cells for high-risk multiple myeloma at AACR 2026. It will also showcase its Dagger® gene-edited platform’s extension into autoimmune disease and lead April 21 sessions on off-the-shelf CAR T scalability.
1. Preclinical Evaluation at AACR Poster Session
On April 20, Mark K. O’Dair, PhD, will present Poster #1535 (Section 7, Board 17) detailing preclinical evaluation of BCMA/CD70 dual AlloCAR T cells for high-risk multiple myeloma, highlighting gene-edited, dual-targeting to improve persistence and reduce lymphodepletion.
2. Dagger® Platform Extension into Autoimmune Disease
Allogene is applying its Dagger® technology to autoimmune disease by targeting BCMA and CD70 on plasma cells while selectively eliminating alloreactive immune cells, aiming for durable persistence with reduced chemotherapy-based lymphodepletion.
3. Major Symposium on Off-the-Shelf Cell Therapies
On April 21 from 12:30–2:00 pm PT in Room 28, President and CEO David Chang, M.D., Ph.D., will lead ‘Allogeneic CAR-T: Science at Scale,’ focusing on speed, safety, simplicity, scalability and survival of off-the-shelf CAR T.
4. Forum on Cell Therapy Evolution
Also on April 21 from 5:00–6:30 pm PT in Ballroom 20 AB, EVP and CMO Zachary Roberts, M.D., Ph.D., will explore the evolving landscape between autologous, allogeneic and in vivo engineering, positioning off-the-shelf AlloCAR T as a manufacturing bridge to meet growing patient demand.